Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • GSK Consumer...

    GSK Consumer Healthcare Q4 profit up 35 percent to Rs 285 crore

    GarimaWritten by Garima Published On 2019-05-11T09:35:42+05:30  |  Updated On 16 Aug 2021 12:04 PM IST

    In a separate filing, GSK Consumer Healthcare informed that its board has recommended a dividend at the rate of Rs 105 per equity share of Rs 10 each.


    New Delhi: Glaxo Smith Kline (GSK) Consumer Healthcare on Friday reported 34.93 per cent increase in standalone net profit at Rs 285.81 crore for the fourth quarter ended March 31, 2019.


    The company clocked a profit of Rs 211.81 crore in the January-March quarter a year ago, it said in a BSE filing.


    Read Also: GSK expects shingles drug sales to exceed $1.3 billion


    Total income in the latest quarter was up 11.48 per cent to Rs 1,408.95 crore as against Rs 1,263.75 crore in the year-ago period.


    Total expenses in the March quarter 2019 were Rs 982.70 crore, up 4 per cent from Rs 944.86 crore in the year-ago period.


    For 2018-19, the company registered a profit of Rs 982.80 crore, a rise of 40.37 per cent from Rs 700.10 crore logged in 2017-18.


    Read Also: GSK gets USFDA nod for HIV-1 drug branded as Dovato


    Total income during 2018-19 stood at Rs 5,214.61 crore as against Rs 4,634.46 crore in the previous year.


    In a separate filing, GSK Consumer Healthcare informed that its board has recommended a dividend at the rate of Rs 105 per equity share of Rs 10 each.


    Shares of the company settled at Rs 7,035.85 per scrip on BSE, down 0.70 per cent from the previous close.


    Read Also: HUL expects to complete merger with GSK Consumer Healthcare in 2019

    BSEconsumerconsumer healthcarefourth quarter resultsGlaxo Smith KlineGSKGSK Consumer HealthcareGSK dividendGSK financial statementGSK healthcaregsk net profitGSK Q4HealthcareShares of GSK
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok